CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
4.240
+0.430 (11.29%)
At close: Jun 18, 2026, 4:00 PM EDT
3.920
-0.320 (-7.55%)
After-hours: Jun 18, 2026, 7:59 PM EDT
CervoMed Revenue
CervoMed had revenue of $2.09M in the twelve months ending March 31, 2026, down -77.56% year-over-year. In the year 2025, CervoMed had annual revenue of $4.01M, down -58.86%.
Revenue (ttm)
$2.09M
Revenue Growth
-77.56%
P/S Ratio
26.90
Revenue / Employee
$139,268
Employees
15
Market Cap
39.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.01M | -5.73M | -58.86% |
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 71.67K | -302.88K | -80.87% |
| Dec 31, 2012 | 374.54K | -195.93K | -34.35% |
| Dec 31, 2011 | 570.48K | 530.29K | 1,319.48% |
| Dec 31, 2010 | 40.19K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 40.19K | -268.57K | -86.98% |
| Dec 31, 2007 | 308.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Palatin Technologies | 12.88M |
| Marker Therapeutics | 3.55M |
| Longeveron | 1.22M |
| Vistagen Therapeutics | 789.00K |
| Allarity Therapeutics | 345.00K |
| Neuphoria Therapeutics | -13.27K |
CRVO News
- 8 hours ago - CervoMed announces $10M registered direct offering priced at-the-market - TheFly
- 9 hours ago - CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 14 hours ago - CervoMed receives notice of allowance from USPTO on neflamapimod - TheFly
- 14 hours ago - CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042 - GlobeNewsWire
- 3 days ago - CervoMed Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 6 days ago - CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - GlobeNewsWire
- 8 days ago - CervoMed announces $10.5M private placement - TheFly
- 8 days ago - CervoMed announces $10.5M private placement - TheFly